GlassScriptPhysician profile
Michael A Volz
NPI 1841225430
$77,585.96
in general payments reported to CMS, 2019-2025
27 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $10K · 2021: $9,679 · 2022: $10K · 2023: $23K · 2024: $2,851 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $3,985 · Food and Beverage: $2,276 · Consulting Fee: $1,980 · Education: $37.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,042.50 |
| Travel and Lodging | $3,985.18 |
| Food and Beverage | $2,275.97 |
| Consulting Fee | $1,980.00 |
| Education | $37.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $34,272.23 | 2019-2024 | Hizentra, Haegarda |
| Grifols USA, LLC | $25,496.95 | 2019-2023 | Xembify, Prolastin-C Liquid |
| Biocryst Pharmaceuticals, INC. | $6,269.43 | 2019-2020 | |
| Pharming Healthcare, INC. | $2,244.64 | 2021-2023 | Ruconest |
| Pfizer INC. | $2,202.76 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,146.56 | 2019-2024 | Fasenra, Evusheld, Breztri |
| Biocryst US Sales Co., LLC | $1,100.99 | 2021-2023 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $1,067.44 | 2020-2024 | Hyqvia, Takhzyro, Cuvitru |
| Glaxosmithkline, LLC. | $732.96 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $558.98 | 2019-2024 | Dupixent |
| Octapharma USA, INC. | $405.23 | 2019-2023 | Cutaquig |
| Bio Products Laboratory USA, INC. | $295.18 | 2019-2023 | Coagadex, Gammaplex |
| Kaleo, INC. | $278.75 | 2019-2022 | |
| Genzyme Corporation | $266.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.22 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $239.20 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $131.50 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $104.86 | 2020-2021 | |
| Amgen INC. | $99.80 | 2022-2023 | Tezspire |
| Sunovion Pharmaceuticals INC. | $97.38 | 2019 | |
| Adma Biomanufacturing LLC | $94.69 | 2021-2022 | |
| Shire North American Group INC | $62.56 | 2019 | |
| Alk-Abello, INC | $53.12 | 2024-2025 | Odactra, Ragwitek, Grastek |
| Abbvie INC. | $50.57 | 2023 | Rinvoq |
| Mylan Specialty L.P. | $32.59 | 2020-2021 | |
| Phadia US INC. | $18.56 | 2023 | Immunocap |
| Merck Sharp & Dohme LLC | $17.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Volz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.